EValuation of Acute and Early Phase P2Y12 Inhibitor DE-escalation After Percutaneous Intervention (EVADE PCI)

A composite outcome of all-cause mortality, urgent revascularization, stent thrombosis, stroke, and major bleeding at one year was similar between patients who continued ticagrelor or prasugrel and those de-escalated to clopidogrel within 30 days of PCI. Larger studies are needed to confirm these findings and assess the optimal timing for therapy adjustments.